Cangene vaccinia immune globulin I.V. approved
FDA grants accelerated approval for Cangene's CNJ-016 (vaccinia immune globulin intravenous) for the treatment of smallpox vaccination complications May 3. It is the second VIGIV biologics license application granted accelerated approval; the agency approved DynPort's VIGIV Feb. 18. Both approvals were based on limited pharmacokinetic and pharmacodynamic data and require the sponsors to conduct confirmatory trials. Cangene developed the product under a 2002 contract with the Centers for Disease Control & Prevention. The contract allows CDC to order a total of up to 100,000 doses through 2007...
You may also be interested in...
Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.
The head of the US Food and Drug Administration praised the life-saving work of device center staff in response to the coronavirus pandemic.
Decision on Regeneron’s Ebola virus therapy, which uses a similar monoclonal antibody cocktail approach as the company’s COVID-19 therapy candidate, stands out among the 10 user fee goal dates in the coming month.